Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124657 · ClinicalTrials.gov registry record · Phase 1
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00124657 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 62 participants.
The verdict
NCT00124657, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with erlotinib may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with radiation therapy and to see how well they work in treating young patients with newly diagnosed glioma.
Interventions
- DRUG Erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2005-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124657
The ClinicalTrials.gov registry entry for NCT00124657 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib hydrochloride is the first listed.
NCT00124657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124657 about?
NCT00124657 is a clinical study titled "Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It may also make tumor cells more sensitive to radiation therapy. Giving radiation th...
What is the current status of trial NCT00124657?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2005-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00124657?
The interventions under investigation include: Erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00124657?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.